Outlook Therapeutics, Inc. OTLK
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2016 · data as of November 13, 2026
Outlook Therapeutics, Inc. (OTLK) is a healthcare company listed in the US with a market value of about $101M. In fiscal year 2025 it had revenue of $1M and net income of -$62M, a net margin of -4416.2%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -232%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Outlook Therapeutics
Outlook Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2016. Revenue went from $5M in 2015 to $1M in 2025, a decline of about 12.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 228% over three years (dilution for shareholders). It spends 1923% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | — | — | — | — | — | $8M | $3M | $4M | $3M |
| Net income | -$62M | -$75M | -$59M | -$66M | -$53M | -$35M | -$35M | -$30M | -$39M | -$53M |
| Free cash flow | — | — | — | — | — | — | -$33M | -$36M | -$16M | -$47M |
| EPS (diluted) | $-1.79 | $-4.06 | $-4.72 | $-6.20 | $-7.00 | $-13.40 | $-39.60 | $-24.40 | $-36.00 | $-73.40 |
| Net margin | -4416.2% | — | — | — | — | — | -423.8% | -974.6% | -1019.3% | -1788.9% |
| ROIC | — | — | -198.8% | -250.7% | -247.4% | -849.5% | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Outlook Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Outlook Therapeutics pay a dividend?
Not currently.
Is Outlook Therapeutics a good stock to buy?
We do not give buy or sell advice. Outlook Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.